"As a 484-bed acute care medical center located on the Buffalo Niagara Medical Campus in downtown Buffalo, NY, BGMC/GVI provides the latest treatment options, technology and expert physicians."

During the past decade, Buffalo General Medical Center conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 16 clinical trials were completed, i.e. on average, 57.1% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 9 clinical trials were completed. i.e. 56.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Buffalo General Medical Center" #1 sponsor was "Abbott Medical Devices" with 6 trials, followed by "State University of New York at Buffalo" with 4 trials sponsored, "Astellas Pharma Inc" with 3 trials sponsored, "Boston Scientific Corporation" with 3 trials sponsored and "Bolton Medical" with 3 trials sponsored. Other sponsors include 27 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Buffalo General Medical Center" #1 collaborator was "National Institute of Neurological Disorders and Stroke (NINDS)" with 6 trials as a collaborator, "Medical University of South Carolina" with 5 trials as a collaborator, "Neurological Emergencies Treatment Trials Network (NETT)" with 3 trials as a collaborator, "Astellas Pharma US, Inc." with 2 trials as a collaborator and "Pfizer" with 2 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "Buffalo General Medical Center" are "Ischemic Stroke" (5 trials), "Stroke" (5 trials), "Acute Ischemic Stroke" (2 trials), "Atrial Fibrillation" (2 trials) and "Bleeding" (2 trials). Many other conditions were trialed in "Buffalo General Medical Center" in a lesser frequency.

Most popular intervention types in "Buffalo General Medical Center" are "Device" (20 trials), "Drug" (20 trials), "Procedure" (5 trials), "Other" (4 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Apixaban" (3 trials), "Aspirin" (3 trials), "placebo" (3 trials) and "AMPLATZER™ Post-infarct Muscular VSD Occluder" (1 trials). Other intervention names were less common.

The vast majority of trials in "Buffalo General Medical Center" are 50 trials for "All" genders.

Currently, there are NaN active trials in "Buffalo General Medical Center". undefined are not yet recruiting, 10 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in Buffalo General Medical Center, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Buffalo General Medical Center, 1 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 16 trials that are defined as “Not Applicable".